Avoro Capital Advisors
110 Greene Street, Suite 800, New York, NY, 10012, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Hemab | Oct 2025Participated | $157 MSeries C | |
Ottimo Pharma | Dec 2024Led | $140 MSeries A | |
Nuvalent | May 2021Participated | $135 MSeries B | |
Monte Rosa Therapeutics | Mar 2021Led | $95 MSeries C | |
Vividion Therapeutics | Feb 2021Participated | $135 MSeries C | |
Design Therapeutics | Jan 2021Participated | $125 MSeries B | |
IO Biotech | Jan 2021Participated | $155 MSeries B | |
Olema Oncology | Oct 2020Participated | $85 MSeries C | |
PMV Pharmaceuticals | Aug 2020Participated | $70 MSeries D | |
Praxis Precision Medicines | Jul 2020Participated | $110 MSeries C | |
Hemab | Oct 2025Participated | $157 MSeries C | |
Ottimo Pharma | Dec 2024Led | $140 MSeries A | |
Nuvalent | May 2021Participated | $135 MSeries B | |
Monte Rosa Therapeutics | Mar 2021Led | $95 MSeries C | |
Vividion Therapeutics | Feb 2021Participated | $135 MSeries C | |
Design Therapeutics | Jan 2021Participated | $125 MSeries B | |
IO Biotech | Jan 2021Participated | $155 MSeries B | |
Olema Oncology | Oct 2020Participated | $85 MSeries C | |
PMV Pharmaceuticals | Aug 2020Participated | $70 MSeries D | |
Praxis Precision Medicines | Jul 2020Participated | $110 MSeries C |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 1 | 0 |
| Series B | 0 | 3 |
| Series C+ | 1 | 5 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jul '20 | 1 |
| Aug '20 | 1 |
| Sep '20 | 0 |
| Oct '20 | 1 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 2 |
| Feb '21 | 1 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 10 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 0 |
| $50M-$100M | 3 |
| $100M-$250M | 7 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 6 |
| Europe | 4 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| RA Capital Management | 6 |
| BlackRock | 4 |
| Cormorant Asset Management | 4 |
| Janus Henderson Investors | 4 |
| Logos Capital | 4 |
| Surveyor Capital | 4 |
| Boxer Capital | 3 |
| OrbiMed | 3 |
| T. Rowe Price Associates | 3 |
| Vivo Capital | 3 |
| Wellington Management | 3 |
| BVF Partners | 2 |
| Casdin Capital | 2 |
| Deerfield Management | 2 |
| Driehaus Capital Management | 2 |
| Fidelity Management & Research Company | 2 |
| HBM Healthcare Investments | 2 |
| Invus | 2 |
| Novo Holdings | 2 |
| RTW Investments | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 2 | 20% |
| Participating | 8 | 80% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 50% |
| Co-led | 1 | 50% |
Team
Managing Partner & Founder
Partner
Partner, Chief Financial Officer & Chief Compliance Officer
Partner, Avoro Ventures